Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRILI: Pirfenidone for Prophylaxis Against Acute Radiation-induced Lung Injury in Breast Cancer
NCT05704166Phase 2Recruiting
- Sponsor
- Fujian Medical University Union Hospital
- Start
- Mar 2023
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pirfenidone in radiation-induced lung injury (RILI), sponsored by Fujian Medical University Union Hospital. Started Mar 2023; status: recruiting.
02
Drugs
pirfenidone
03
Conditions
radiation-induced lung injury (RILI)
Beyond the preview
Go deeper on NCT05704166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05704166.